Although the duplication of KMT2A is a rare molecular event in childhood leukemia, multiple case reports showed that patients with KMT2A::MLLT10 duplication remained in first complete remission with negative minimal residual disease at 3.5 years from diagnosis (34, 35). This evidence concerns the gene MLLT10 and leukemia.